Fluorodeoxyglucose 18 (18F-FDG)
ID: W81K0224Q0103Type: Sources Sought
Overview

Buyer

DEPT OF DEFENSEDEPT OF THE ARMYW40M MRCO PACIFICFORT SHAFTER, HI, 96858-5098, USA

Original Source

https://sam.gov/opp/0daad92c64bf44aea3d2ba2fa0111ebb/view
Timeline
    Description

    The Department of Defense, specifically the Department of the Army, is planning to award a sole source contract for Fluorodeoxyglucose-18 (FDG-18) to Hamamatsu-Queen's PET Imaging Center for use at Tripler Army Medical Center in Hawaii. This procurement, which falls under the NAICS code 325412, is intended to support medical readiness and will span from October 1, 2024, through September 30, 2029, including four one-year option periods. FDG-18 is a critical radiopharmaceutical used in positron emission tomography (PET) imaging, essential for various diagnostic procedures. Interested parties may submit capability statements or quotations for consideration, and all inquiries should be directed to Wendi Young-Asao at wendi.t.young-asao.civ@health.mil.

    Point(s) of Contact
    Wendi Young-Asao
    wendi.t.young-asao.civ@health.mil
    Files
    No associated files provided.
    Lifecycle
    Title
    Type
    Fluorodeoxyglucose-18
    Presolicitation
    Fluorodeoxyglucose 18 (18F-FDG)
    Currently viewing
    Sources Sought
    Similar Opportunities
    6505--Lymphoseek IDIQ
    Active
    Veterans Affairs, Department Of
    The Department of Veterans Affairs, specifically the Network Contracting Office 22, intends to award a Sole Source contract for the procurement of Lymphoseek, a proprietary radiopharmaceutical, primarily for use at the VA Loma Linda Healthcare System. This contract, designated as Solicitation Number 36C26225Q0026, will be structured as a Firm Fixed-Price Indefinite Quantity Indefinite Delivery (IDIQ) with a base year and four option years, with an estimated quantity of 86 study doses required annually. Lymphoseek is critical for identifying sentinel lymph nodes in melanoma patients, providing superior image quality due to its targeted action on the CD206 receptor. Interested parties may submit a capabilities statement by September 27, 2024, at 10:00 AM Pacific Time, and should direct inquiries to Hestia Sim at Hestia.Sim@va.gov.
    6505--Supply, Axumin-Axumin + Cerianna Medicines - Nuclear Med, CLE
    Active
    Veterans Affairs, Department Of
    The Department of Veterans Affairs intends to solicit and negotiate exclusively with PetNet Solutions and TrillaMed for the supply of three proprietary radiopharmaceuticals—Axumin, Amyvid, and Cerianna—for the Nuclear Medicine Service at the Louis Stokes Cleveland VA Medical Center. These products are critical for diagnosing recurrent prostate cancer, breast cancer, and Alzheimer’s disease, necessitating the use of a local radiopharmacy due to their radioactive nature and short shelf life. Interested vendors may submit their capabilities until September 18, 2024, to determine if a competitive procurement process is feasible, with all inquiries directed to Contract Specialist Don Caldwell at don.caldwell@va.gov.
    Q527--Intent to Sole Source Radiopharm Isotopes-Wilkes-Barre VAMC
    Active
    Veterans Affairs, Department Of
    The Department of Veterans Affairs, through Network Contracting Office 4, intends to issue a sole source contract for the provision of Radiopharmaceutical Isotopes to the Wilkes-Barre VA Medical Center, specifically with Jubilant Draximage Radiopharmaceuticals Inc. The contract aims to ensure the timely delivery of radiopharmaceuticals that comply with U.S. Nuclear Regulatory Commission (NRC) and Food and Drug Administration (FDA) regulations, thereby prioritizing patient safety and effective healthcare for veterans. This procurement is critical for maintaining high-quality medical services, as the contractor will be required to adhere to strict quality control measures, provide emergency services, and ensure proper packaging and labeling of all materials supplied. Interested vendors must submit a capability statement by September 20, 2024, to the Contracting Specialist, Christa Stine, at christa.stine@va.gov.
    Pharmaceutical Preparation Manufacturing
    Active
    Dept Of Defense
    Sources Sought DEPT OF DEFENSE DEFENSE LOGISTICS AGENCY is seeking local sources capable and interested in fulfilling a requirement for the procurement and delivery of CLASS VIII, Medical Laboratory Reagents, in support of United States Naval Hospital (USNH), located in Okinawa, Japan. The procurement is for ULTRA TECHNE KOW 18.5GBq Injection Generator, with an estimated quantity of 26 units per year. The delivery location will be the United States Naval Hospital (USNH) Okinawa Nuclear Medicine Department, Camp Foster, Okinawa, Japan. Interested parties should provide company information, capability to provide the items, and item lead times. Responses must be submitted by Thursday, November 09, 2023, via email to jasielle.castro@dla.mil and mamiko.jackson@dla.mil.
    Reference Laboratory Testing Services
    Active
    Dept Of Defense
    The Department of Defense, through the Defense Health Agency (DHA), intends to award a sole source contract for Reference Laboratory Testing Services to Diagnostic Laboratory Services, Inc. This contract will support the Laboratory Department at Naval Hospital Guam by providing comprehensive diagnostic testing and specialized laboratory services, including blood tests, genetic testing, and microbiology, which are critical for ensuring timely and accurate patient diagnoses. The contract is set to begin on September 19, 2024, with options for extension through September 30, 2026, and interested vendors must submit capability statements by 1:00 PM Pacific Daylight Time on September 12, 2024, to Merlinda Labaco at merlinda.m.labaco.civ@health.mil for consideration.
    6505--Notice of Intent to Sole Source Pluvicto and Lutathera
    Active
    Veterans Affairs, Department Of
    The Department of Veterans Affairs (VA) intends to award a sole source contract to Advanced Accelerator Applications USA for the provision of Pluvicto and Lutathera, specialized radiopharmaceuticals used in the treatment of metastatic castration-resistant prostate cancer and gastroenteropancreatic neuroendocrine tumors. This procurement is justified under FAR regulations due to the unique and highly specialized nature of the therapies required, which limits the availability of suitable suppliers. Interested parties are invited to submit their capability statements, including qualifications and relevant contract information, by 10:00 AM PT on September 25, 2024, to Peter Kim at peter.kim33@va.gov. The contracting office is located in Long Beach, CA, and responses must be submitted electronically; failure to respond may result in the contract being awarded without further solicitation.
    Maintenance for fMRI software
    Active
    Dept Of Defense
    The Defense Health Agency (DHA) intends to award a sole source contract to Nordic Neuro Lab, Inc. for maintenance services related to the existing NordicBrain software and hardware at Walter Reed National Military Medical Center (WRNMMC) in Bethesda, Maryland. This procurement aims to ensure ongoing support and maintenance of specialized medical software and hardware that are critical for the operations of the Radiology Department at WRNMMC. The contract will be awarded under the authority permitting Other than Full and Open Competition, with interested parties required to express their capabilities by 10:00 AM EST on September 19, 2024, via email to the primary contact, Ealed Nuru, at ealed.m.nuru.civ@health.mil, with a copy to Erica S. Oh at erica.s.oh.civ@health.mil.
    Medical Lab Technician and Medical Lab Technologists
    Active
    Dept Of Defense
    The Department of Defense, through the Defense Health Agency (DHA), is seeking to negotiate a sole-source contract with Distinctive Health Spectrum Care JV LLC for the provision of medical laboratory personnel at the Naval Hospital Guam. The procurement aims to add two Medical Lab Technologists and one Medical Lab Technician under contract HT001418D0029, Task Order N6264521F0140, for the period from October 1, 2024, to June 27, 2025, reflecting the critical need for laboratory testing services in a military healthcare setting. Interested parties may submit capability statements for consideration, although the government may opt not to pursue competitive proposals based on the responses received, with a deadline for challenges set for September 26, 2024. For further inquiries, interested vendors can contact Uyen Tran at uyen.t.tran6.civ@health.mil.
    Avalon FM50 Fetal Heart Monitor
    Active
    Dept Of Defense
    The Department of Defense, through the Defense Health Agency (DHA), is seeking qualified vendors to provide the Philips Avalon FM50 Fetal Heart Monitor and associated equipment for the United States Naval Hospital in Guam. This procurement is essential for enhancing maternal and fetal care, particularly for high-risk pregnancies, as the monitor offers unique features such as simultaneous monitoring of multiple fetuses and advanced diagnostic capabilities. Interested vendors must comply with federal regulations, including registration in the System for Award Management (SAM), and submit their quotes electronically by noon on September 23, 2024, detailing their technical capabilities and pricing. For further inquiries, vendors can contact Merlinda Labaco at merlinda.m.labaco.civ@health.mil or Renier Valdez at renier.s.valdez.civ@health.mil.
    Q522--PHARMACUTICAL, STL 657-24-3-1642-0121, (VA-25-00001168)
    Active
    Veterans Affairs, Department Of
    The Department of Veterans Affairs is seeking responses to a Sources Sought Notice for a contract involving the provision of a proprietary radiopharmaceutical agent, Pluvicto, for the St. Louis VA Medical Center. This contract will cover a base year plus four option years for the supply of Lutetium LU 177 Vipivvotide Tetraxetan, which is critical for treating adult patients with prostate-specific membrane antigen (PSMA) positive metastatic castration-resistant prostate cancer. The selected contractor will be responsible for administering this radioactive diagnostic therapy via IV, with all contract administration functions retained by the Department of Veterans Affairs. Interested parties must submit their responses by September 20, 2024, at 3:00 PM CST, to Michael P. Murphy at michael.murphy7@va.gov, including their Unique Entity ID and relevant qualifications.